Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV brincidofovir in relapsed or refractory lymphoma (including ENKL)
jRCT2061240096Phase 2Suspended
- Sponsor
- SymBio Pharmaceuticals
- Start
- Jun 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of brincidofovir in lymphoma, extranodal natural killer/T-cell lymphoma (ENKTL), nodal NK/T-cell lymphoma (nNKTL) and 6 more (2 arms), sponsored by SymBio Pharmaceuticals. Started Jun 2025; status: suspended.
02
Drugs
brincidofovir
03
Conditions
lymphomaextranodal natural killer/T-cell lymphoma (ENKTL)nodal NK/T-cell lymphoma (nNKTL)follicular T-cell lymphoma (FTCL)angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on jRCT2061240096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240096.